Latest Healthcare Research Reports

Tag: research and development

Immuno-Oncology Drugs Market Forecast 2026: Market Size, Competitive Landscape And Growth Drivers

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Immuno-Oncology Drugs Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The immuno-oncology drugs market size has experienced rapid growth in recent years. It is anticipated to increase from $120.37 billion in 2025 to $136.15 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.1%. This historical expansion can be ascribed to several factors, including the initial limited availability of immuno-oncology drugs, a reliance on conventional chemotherapy, the rising prevalence of cancers such as melanoma and lung cancer, expanding oncology-focused research initiatives, and early regulatory approvals granted for monoclonal antibodies.

The immuno-oncology drugs market size is anticipated to experience substantial growth in the coming years. It will grow to $226.31 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. This growth throughout the forecast period can be attributed to advancements such as the development of bispecific antibodies and oncolytic virus therapies, the expansion of personalized immunotherapy solutions, increasing investment in adoptive cell transfer therapies, rising healthcare expenditure on cancer treatment, and the integration of digital platforms for patient monitoring and clinical trials. Furthermore, major trends in the forecast period encompass the rising adoption of immune checkpoint inhibitors across multiple cancer types, increased development of cancer vaccines and adoptive cell therapies, a growing focus on personalized immuno-oncology treatments, the expansion of hospital and ambulatory surgical center-based immunotherapy programs, and rising clinical trials and research activities involving monoclonal antibodies.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=36536819&type=smp&name=Immuno-Oncology%20Drugs%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Immuno-Oncology Drugs Market Growth Backed By Core Demand Fundamentals

The rising occurrence of cancer cases is anticipated to spur expansion within the immuno-oncology drugs market in the coming years. Cancer is characterized by the uncontrolled proliferation of anomalous cells, which can potentially disseminate throughout the body and disrupt normal physiological functions. The rise in cancer diagnoses stems from elements like an aging global demographic, evolving lifestyle habits, and advancements in detection techniques. Immuno-oncology drugs address this challenge by activating the body’s own immune defenses to identify and eradicate cancerous cells, thereby offering more potent and targeted therapeutic avenues. For example, in 2023, Cancer Australia, an Australia-based government agency, reported approximately 164,694 new cancer cases diagnosed and 51,269 deaths. The most prevalent forms were prostate, breast, melanoma, colorectal, and lung cancers, whereas rare cancers represented about one-third of diagnoses and 42% of fatalities. Consequently, the growing frequency of cancer cases is a significant catalyst for the immuno-oncology drugs market.

Immuno-Oncology Drugs Market Segments: Where Is Growth Concentrated?

The immuno-oncology drugs market covered in this report is segmented –

1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Other Types

2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application

3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors

3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies

4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

5) By Other Types: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies

Immuno-Oncology Drugs Market Growth Trends Reshaping The Competitive Landscape

Leading companies within the immuno-oncology drugs market are entering collaborations to create and bring to market a novel checkpoint antibody, aiming to boost the effectiveness of cancer treatments. These strategic alliances promote innovation through the exchange of knowledge across various disciplines, which contributes to the quicker development of combination therapies, customized treatments, and advanced drug delivery systems. For instance, in March 2023, BioNTech SE, a Germany-based company, formed a partnership with OncoC4 Inc, a US-based pharmaceutical company, to jointly develop and commercialize a checkpoint antibody, specifically the anti-CTLA-4 monoclonal antibody candidate known as ONC-392. The objective of this partnership is to improve cancer treatment options across numerous solid tumor indications.

Immuno-Oncology Drugs Market Key Participants And Competitive Landscape

Major companies operating in the immuno-oncology drugs market are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals.

View The Full Immuno-Oncology Drugs Market Report:

https://thebusinessresearchcompany.com/report/Immuno-Oncology-Drug-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Immuno-Oncology Drugs Market Largest Region By Revenue And Market Share

North America was the largest region in the immuno-oncology drugs market in 2025. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

October 13, 2026
Cancer Therapy Market Size And Growth In 2026: Key Factors Shaping Future Demand

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Cancer Therapy Market Growth From $232.46 Billion In 2026 To $342.09 Billion By 2030 At A CAGR Of 10.1%

The cancer therapy market has experienced rapid expansion in recent years. It is anticipated to increase from $210.44 billion in 2025 to $232.47 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.5%. The growth observed in previous periods is primarily due to rising cancer incidence, the adoption of chemotherapy, improved hospital oncology infrastructure, the expansion of radiation therapy, and an aging population.

The cancer therapy market is projected to experience substantial expansion in the coming years, reaching a valuation of $342.1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.1%. This anticipated growth during the forecast period is driven by factors such as biomarker-driven therapies, advancements in the immuno-oncology pipeline, the increasing adoption of precision medicine, rising healthcare expenditure, and improved early cancer detection methods. Key developments expected during this period include the accelerated uptake of immunotherapy, the proliferation of targeted cancer treatments, the broadening scope of precision oncology, a greater reliance on combination therapies, and a pivot towards individualized treatment plans.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24492&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Cancer Therapy Market Growth Drivers: What’s Behind The Acceleration?

The increasing prevalence of cancer is projected to fuel the expansion of the cancer therapy market. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rise in cancer cases is primarily attributed to heightened exposure to environmental carcinogens like pollution and tobacco smoke. Cancer therapy plays a crucial role in managing the increasing prevalence of cancer by treating existing conditions, enhancing survival rates, and slowing disease progression. For instance, in February 2024, the World Health Organization (WHO), an intergovernmental organization based in Switzerland, reported that global cancer incidence is anticipated to reach over 35 million new cases by 2050, signifying a 77% increase from the estimated 20 million cases recorded in 2022. Therefore, the growing prevalence of cancer acts as a key driver for the cancer therapy market.

Cancer Therapy Market Segment Analysis Spotlighting Growth Areas

The cancer therapy market covered in this report is segmented –

1) By Therapy Type: Chemotherapy, Target Therapy, Immunotherapy, Radiotherapy, Other Therapy Types

2) By Cancer Type: Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynaecologic Cancer, Respiratory Or Lung Cancer, Other Cancer Types

3) By End User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers

Subsegments:

1) By Chemotherapy: Alkylating Agents, Antimetabolites, Anti-Tumor Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors, Corticosteroids, Other Chemotherapy Drugs

2) By Targeted Therapy: Monoclonal Antibodies, Tyrosine Kinase Inhibitors (TKIs), mTOR Inhibitors, Proteasome Inhibitors, PARP Inhibitors, Other Targeted Agents

3) By Immunotherapy: Immune Checkpoint Inhibitors, CAR T-cell Therapy, Cancer Vaccines, Cytokines, Oncolytic Virus Therapy, Other Immunotherapies

4) By Radiotherapy: External Beam Radiation Therapy (EBRT), Internal Radiation Therapy (Brachytherapy), Systemic Radiation Therapy, Stereotactic Radiosurgery (SRS), Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT)

5) By Other Therapy Types: Hormone Therapy, Stem Cell Transplant, Photodynamic Therapy, Cryoablation, Hyperthermia Therapy

Cancer Therapy Market Trends: What’s Defining The Industry’s Next Phase?

Major companies operating in the cancer therapy market are increasingly focusing on developing innovative therapies, such as immuno-oncology drugs, to enhance treatment effectiveness by leveraging the body’s immune system to target and destroy cancer cells. Immuno-oncology drugs constitute a class of cancer treatments designed to stimulate or boost the body’s own immune system to more effectively recognize and attack cancer cells. For instance, in December 2024, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical company, introduced Toripalimab in India, marking it as the first and only immuno-oncology medication authorized for the treatment of nasopharyngeal cancer. This launch provides a new, targeted treatment option for patients suffering from this rare and aggressive cancer, with the potential to improve outcomes through advanced immune system engagement. The availability of toripalimab in India underscores Dr. Reddy’s commitment to expanding access to cutting-edge cancer therapies in underserved areas.

Cancer Therapy Market Leading Companies: Who Holds The Strongest Market Presence?

Major companies operating in the cancer therapy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Elekta AB, Exelixis Inc., Accuray Incorporated, Akeso Inc., Nanobiotix S.A., SOTIO Biotech a.s., AdvanCell Isotopes Pty Ltd, Axcynsis Therapeutics Pte Ltd, Clarity Pharmaceuticals Ltd, Affimed N.V., Aptadel Therapeutics S.L.

View The Full Cancer Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-therapy-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Cancer Therapy Market Regional Breakdown: Where Is Demand Concentrated?

North America was the largest region in the cancer therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

October 9, 2026
Immuno-Oncology Drugs Market Forecast Highlights Expansion From $136.15 Billion To $226.3 Billion Through 2030

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Immuno-Oncology Drugs Market Value Expansion And Long-Term Growth Outlook

The market for immuno-oncology drugs has experienced rapid expansion over the past few years. Its value is projected to increase from $120.37 billion in 2025 to $136.15 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.1%. This historic growth has been driven by factors such as the constrained supply of these therapies, a dependence on traditional chemotherapy, a rising incidence of cancers including melanoma and lung cancer, an uptick in oncology-related research programs, and early-stage regulatory clearances for monoclonal antibodies.

The immuno-oncology drugs market is anticipated to experience significant expansion over the coming years, with projections indicating it will reach $226.31 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.5%. This forecasted growth is fueled by advancements such as the creation of bispecific antibodies and oncolytic virus therapies, broader deployment of personalized immunotherapy options, greater investments in adoptive cell transfer methods, increased healthcare spending dedicated to cancer care, and the incorporation of digital tools for patient observation and clinical study management. Key trends shaping this period include the widespread use of immune checkpoint inhibitors across diverse cancer types, accelerated development of cancer vaccines and adoptive cell treatments, heightened emphasis on tailored immuno-oncology approaches, expansion of immunotherapy programs within hospitals and ambulatory surgical centers, and a surge in clinical trials and research activity focusing on monoclonal antibodies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Immuno-Oncology Drugs Market Demand Drivers: What Is Fueling Industry Growth?

The anticipated rise in cancer diagnoses will likely accelerate the expansion of the immuno-oncology drugs market in the future. Cancer involves the uncontrolled growth of abnormal cells, which can invade other parts of the body and disrupt normal physiological processes. An increase in cancer cases is driven by factors like an aging demographic, lifestyle shifts, and enhanced screening techniques that detect the disease earlier. Immuno-oncology medications advance this trend by activating the immune system to precisely identify and destroy malignant cells, offering more accurate and effective therapeutic approaches. For example, in 2023, Cancer Australia, a government agency based in Australia, reported that there were approximately 164,694 new cancer diagnoses and 51,269 fatalities, with the most prevalent types being prostate, breast, melanoma, colorectal, and lung cancers, while rarer forms represented roughly one-third of all diagnoses and accounted for 42% of deaths. Consequently, the growing frequency of cancer occurrences is fueling the progress of the immuno-oncology drugs market.

Immuno-Oncology Drugs Market Segment Landscape: Which Areas Lead Market Development?

The immuno-oncology drugs market covered in this report is segmented –

1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Other Types

2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application

3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors

3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies

4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

5) By Other Types: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies

Immuno-Oncology Drugs Market Innovation Trends: Which Developments Are Transforming The Industry?

Major pharmaceutical firms in the immuno-oncology sector are forming alliances aimed at jointly developing and bringing to market a new checkpoint antibody, with the goal of boosting the effectiveness of cancer therapies. Such strategic partnerships facilitate innovation by enabling the exchange of expertise across different disciplines, which accelerates the creation of combination therapies, customized treatment plans, and advanced drug delivery systems. As an example, in March 2023, BioNTech SE, headquartered in Germany, entered into an agreement with OncoC4 Inc, a US-based pharmaceutical organization, to jointly develop and commercialize the anti-CTLA-4 monoclonal antibody candidate ONC-392. This collaboration is intended to expand treatment possibilities for patients with various solid tumors.

Immuno-Oncology Drugs Market Industry Leaders And Market Competition

Major companies operating in the immuno-oncology drugs market are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals.

Access The Complete Immuno-Oncology Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Immuno-Oncology Drugs Market Global Footprint: Which Region Holds Market Leadership?

North America was the largest region in the immuno-oncology drugs market in 2025. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

July 3, 2026
Cancer Therapy Market Expected To Reach $342.09 Billion By 2030 As Growth Accelerates At 10.1% CAGR

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Cancer Therapy Market Size, Value And Growth Trends Through 2030

The cancer therapy market has experienced swift expansion in recent times, with projections indicating growth from $210.44 billion in 2025 to $232.47 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.5%. Several key factors drove this increase during the historic period, including a growing number of cancer cases, the widespread use of chemotherapy, enhanced hospital oncology facilities, the expansion of radiation therapy services, and the effects of an aging population.

The market for cancer therapies is anticipated to experience swift expansion over the coming years, reaching a valuation of $342.1 billion by 2030, progressing at a compound annual growth rate (CAGR) of 10.1%. This projected growth during the forecast period is driven by factors such as biomarker-guided treatments, an expanding immuno-oncology pipeline, the uptake of precision medicine, increasing healthcare spending, and enhanced early cancer detection capabilities. Key developments shaping this period include the swift integration of immunotherapy into clinical practice, the rise of targeted cancer interventions, the broadening scope of precision oncology, a growing emphasis on combined therapeutic approaches, and a notable trend toward customized treatment plans.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24492&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Cancer Therapy Market Development Factors: Which Trends Are Supporting Demand?

The anticipated rise in cancer cases is set to drive expansion in the cancer therapy market moving forward. Cancer encompasses a range of diseases marked by the unregulated growth and dissemination of abnormal cells within the body. This increase in cancer is largely attributed to heightened contact with environmental carcinogens like pollution and tobacco smoke. By treating current cases, enhancing survival rates, and slowing disease advancement, cancer therapy is instrumental in addressing the growing prevalence of the condition. As an example, in February 2024, the World Health Organization (WHO), an intergovernmental body headquartered in Switzerland, projected that global cancer incidence would surpass 35 million new cases by 2050—a 77% jump from the approximate 20 million cases reported in 2022. Consequently, the climbing incidence of cancer is fueling the cancer therapy market.

Cancer Therapy Market Segmentation Trends And Revenue Drivers

The cancer therapy market covered in this report is segmented –

1) By Therapy Type: Chemotherapy, Target Therapy, Immunotherapy, Radiotherapy, Other Therapy Types

2) By Cancer Type: Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynaecologic Cancer, Respiratory Or Lung Cancer, Other Cancer Types

3) By End User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers

Subsegments:

1) By Chemotherapy: Alkylating Agents, Antimetabolites, Anti-Tumor Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors, Corticosteroids, Other Chemotherapy Drugs

2) By Targeted Therapy: Monoclonal Antibodies, Tyrosine Kinase Inhibitors (TKIs), mTOR Inhibitors, Proteasome Inhibitors, PARP Inhibitors, Other Targeted Agents

3) By Immunotherapy: Immune Checkpoint Inhibitors, CAR T-cell Therapy, Cancer Vaccines, Cytokines, Oncolytic Virus Therapy, Other Immunotherapies

4) By Radiotherapy: External Beam Radiation Therapy (EBRT), Internal Radiation Therapy (Brachytherapy), Systemic Radiation Therapy, Stereotactic Radiosurgery (SRS), Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT)

5) By Other Therapy Types: Hormone Therapy, Stem Cell Transplant, Photodynamic Therapy, Cryoablation, Hyperthermia Therapy

Cancer Therapy Market Transformation Trends: Which Innovations Are Driving Change?

Within the cancer therapy market, key players are concentrating their efforts on the development of advanced treatment approaches, particularly immuno-oncology drugs, which are designed to improve therapeutic results by leveraging the body’s immune system to identify and eliminate cancer cells. These immuno-oncology agents represent a specific category of cancer treatments that work by either stimulating or enhancing the natural immune response, enabling it to more effectively recognize and attack malignant cells. A notable example of this trend occurred in December 2024, when Dr. Reddy’s Laboratories Ltd., a pharmaceutical company based in India, launched Toripalimab in the country. This drug is distinguished as the first and only immuno-oncology therapy approved for treating nasopharyngeal cancer, offering a novel and targeted treatment option for patients affected by this uncommon and aggressive form of the disease. By making Toripalimab available, Dr. Reddy’s is demonstrating a clear commitment to providing access to innovative cancer therapies in regions where such advanced treatments have often been limited.

Cancer Therapy Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the cancer therapy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Elekta AB, Exelixis Inc., Accuray Incorporated, Akeso Inc., Nanobiotix S.A., SOTIO Biotech a.s., AdvanCell Isotopes Pty Ltd, Axcynsis Therapeutics Pte Ltd, Clarity Pharmaceuticals Ltd, Affimed N.V., Aptadel Therapeutics S.L.

Access The Complete Cancer Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-therapy-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Cancer Therapy Market Regional Analysis: Which Region Leads By Revenue?

North America was the largest region in the cancer therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

July 1, 2026
Global Surge In Cancer Cases And Its Effect On The Market Is Supporting Development Across The Immuno-Oncology Drugs Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Growth In Market Value Is Anticipated For The Immuno-Oncology Drugs Market Between 2026 And 2030?

The immuno-oncology drugs market size has experienced substantial expansion in recent years. It is projected to increase from $120.37 billion in 2025 to $136.15 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.1%. The historical growth in this market can be linked to factors such as the limited availability of immuno-oncology drugs, a reliance on conventional chemotherapy, the rising prevalence of cancers like melanoma and lung cancer, growing oncology-focused research initiatives, and early regulatory approvals for monoclonal antibodies.

The immuno-oncology drugs market is projected to experience swift expansion in the coming years. Its size is anticipated to reach **$226.31 billion in 2030**, demonstrating a compound annual growth rate (CAGR) of **13.5%**. This growth over the forecast period is attributable to factors such as the development of bispecific antibodies and oncolytic virus therapies, the broadening of personalized immunotherapy solutions, increased investment in adoptive cell transfer therapies, rising healthcare spending on cancer treatment, and the incorporation of digital platforms for patient monitoring and clinical trials. Key trends during this period encompass the increasing adoption of immune checkpoint inhibitors across various cancer types, an upsurge in the development of cancer vaccines and adoptive cell therapies, a heightened emphasis on personalized immuno-oncology treatments, the expansion of hospital and ambulatory surgical center-based immunotherapy programs, and a rise in clinical trials and research initiatives concerning monoclonal antibodies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp

What Important Drivers Are Powering The Immuno-Oncology Drugs Market Growth?

The projected increase in cancer diagnoses is set to boost the expansion of the immuno-oncology drugs market. Cancer is characterized by the uncontrolled multiplication of abnormal cells, potentially migrating to other bodily regions and impairing typical physiological processes. The escalation in cancer cases is attributable to an aging populace, evolving lifestyle habits, and improvements in diagnostic methods. Immuno-oncology drugs contribute to this by stimulating the body’s immune system to identify and eliminate cancer cells, thereby providing more effective and precise treatment options. For instance, in 2023, Cancer Australia, an Australia-based government agency, estimated 164,694 new cancer cases were diagnosed and 51,269 deaths occurred, with prostate, breast, melanoma, colorectal, and lung cancers being the most common, while rare cancers represented about one-third of diagnoses and 42% of deaths. Thus, the rising occurrence of cancer cases is driving the growth of the immuno-oncology drugs market.

How Is The Immuno-Oncology Drugs Market Structured Across Different Market Segments?

The immuno-oncology drugs market covered in this report is segmented –

1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Other Types

2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application

3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors

3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies

4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

5) By Other Types: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies

What Trends Are Influencing The Immuno-Oncology Drugs Market?

Leading companies operating in the immuno-oncology drugs market are forming alliances to develop and bring to market a novel checkpoint antibody, aiming to enhance the effectiveness of cancer treatments. These strategic collaborations stimulate innovation through interdisciplinary knowledge sharing, which leads to the quicker creation of combination therapies, personalized treatments, and advanced drug delivery systems. For example, in March 2023, BioNTech SE, a Germany-based company, joined forces with OncoC4 Inc, a US-based pharmaceutical company, to jointly develop and commercialize a checkpoint antibody, specifically the anti-CTLA-4 monoclonal antibody candidate known as ONC-392. This alliance seeks to improve cancer treatment options for a range of solid tumor indications.

Which Firms Are Competing In The Immuno-Oncology Drugs Market?

Major companies operating in the immuno-oncology drugs market are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals.

Access The Complete Immuno-Oncology Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

Which Regional Market Leads The Immuno-Oncology Drugs Market?

North America was the largest region in the immuno-oncology drugs market in 2025. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Immuno-Oncology Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp

Browse Through More Reports Similar to the Global Immuno-Oncology Drugs Market 2026, By The Business Research Company

Veterinary Laboratory Testing Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-laboratory-testing-services-global-market-report

Dermatitis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Veterinary Diagnostic Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-diagnostic-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

May 19, 2026
Rising Cancer Prevalence Driving Growth Of The Market Due To Aging Population And Growing Treatment Needs Is Supporting Development Across The Cancer Therapy Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Cancer Therapy Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The cancer therapy market size has witnessed rapid growth in recent years. It is forecast to expand from $210.44 billion in 2025 to $232.47 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.5%. This historical growth can be attributed to an increase in cancer incidence, the adoption of chemotherapy, enhancements in hospital oncology infrastructure, the expansion of radiation therapy, and the aging population.

The cancer therapy market size is anticipated to experience substantial growth in the coming years. It is projected to expand to $342.1 billion in 2030, achieving a compound annual growth rate (CAGR) of 10.1%. The expansion during the forecast period is attributable to advancements in biomarker-driven therapies, the development of the immuno-oncology pipeline, wider adoption of precision medicine, increasing healthcare expenditure, and earlier cancer detection. Significant trends expected during this period include the swift embrace of immunotherapy, the rise of targeted cancer treatments, the broadening of precision oncology, a greater reliance on combination therapies, and a transition towards individualized treatment protocols.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24492&type=smp

Which Strategic Drivers Are Supporting The Cancer Therapy Market Development?

The expanding occurrence of cancer is anticipated to drive the cancer therapy market’s growth in the coming years. Cancer defines a category of illnesses marked by the unrestrained proliferation and dissemination of abnormal cells throughout the body. The rise in cancer cases primarily stems from heightened exposure to environmental carcinogens such as air pollution and tobacco smoke. Cancer therapy is instrumental in managing this growing incidence by treating current patients, enhancing their survival rates, and mitigating disease progression. For instance, in February 2024, as reported by the World Health Organization (WHO), a Switzerland-based intergovernmental organization, global cancer incidence is expected to reach over 35 million new cases by 2050, marking a 77% increase from the estimated 20 million cases recorded in 2022. Consequently, the increasing prevalence of cancer is a major force behind the cancer therapy market.

What Segment Types Are Included In The Cancer Therapy Market Analysis?

The cancer therapy market covered in this report is segmented –

1) By Therapy Type: Chemotherapy, Target Therapy, Immunotherapy, Radiotherapy, Other Therapy Types

2) By Cancer Type: Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynaecologic Cancer, Respiratory Or Lung Cancer, Other Cancer Types

3) By End User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers

Subsegments:

1) By Chemotherapy: Alkylating Agents, Antimetabolites, Anti-Tumor Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors, Corticosteroids, Other Chemotherapy Drugs

2) By Targeted Therapy: Monoclonal Antibodies, Tyrosine Kinase Inhibitors (TKIs), mTOR Inhibitors, Proteasome Inhibitors, PARP Inhibitors, Other Targeted Agents

3) By Immunotherapy: Immune Checkpoint Inhibitors, CAR T-cell Therapy, Cancer Vaccines, Cytokines, Oncolytic Virus Therapy, Other Immunotherapies

4) By Radiotherapy: External Beam Radiation Therapy (EBRT), Internal Radiation Therapy (Brachytherapy), Systemic Radiation Therapy, Stereotactic Radiosurgery (SRS), Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT)

5) By Other Therapy Types: Hormone Therapy, Stem Cell Transplant, Photodynamic Therapy, Cryoablation, Hyperthermia Therapy

Which Trends Are Guiding The Development Of The Cancer Therapy Market?

Leading companies in the cancer therapy market are concentrating on developing advanced treatments, particularly immuno-oncology drugs, to improve treatment effectiveness by leveraging the body’s immune system to identify and eliminate cancer cells. Immuno-oncology drugs constitute a class of cancer treatments designed to stimulate or enhance the body’s own immune system, allowing it to more effectively recognize and attack cancerous cells. For example, in December 2024, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical company, introduced Toripalimab, the first and only immuno-oncology medication sanctioned for the treatment of nasopharyngeal cancer, in India. This launch provides a new, targeted therapy option for patients affected by this rare and aggressive cancer, potentially leading to better outcomes through enhanced immune system interaction. The presence of toripalimab in India underscores Dr. Reddy’s commitment to expanding access to cutting-edge cancer therapies in regions that are currently underserved.

Which Companies Are Engaged In The Cancer Therapy Market Environment?

Major companies operating in the cancer therapy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Elekta AB, Exelixis Inc., Accuray Incorporated, Akeso Inc., Nanobiotix S.A., SOTIO Biotech a.s., AdvanCell Isotopes Pty Ltd, Axcynsis Therapeutics Pte Ltd, Clarity Pharmaceuticals Ltd, Affimed N.V., Aptadel Therapeutics S.L.

Access The Complete Cancer Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-therapy-global-market-report

Which Region Accounts For The Highest Share Of The Cancer Therapy Market?

North America was the largest region in the cancer therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Cancer Therapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24492&type=smp

Browse Through More Reports Similar to the Global Cancer Therapy Market 2026, By The Business Research Company

Oncology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-global-market-report

Blood Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Cancer Immunotherapy Drug Discovery Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-drug-discovery-outsourcing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

May 18, 2026
The Immuno-Oncology Drugs Market Is Witnessing Impact From Surging Prevalence Of Cardiovascular Diseases Propels Growth In The Angina Pectoris Drug

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Immuno-Oncology Drugs Market During The Forecast Period?

The immuno-oncology drugs market size has experienced rapid growth in recent years. It is forecast to grow from $120.37 billion in 2025 to $136.15 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.1%. This historical expansion can be attributed to the limited availability of immuno-oncology drugs, a reliance on conventional chemotherapy, the increasing prevalence of cancers such as melanoma and lung cancer, growing oncology-focused research initiatives, and early regulatory approvals for monoclonal antibodies.

The immuno-oncology drugs market is expected to experience significant expansion in the coming years. It is projected to reach $226.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.5%. This growth in the forecast period can be attributed to the development of bispecific antibodies and oncolytic virus therapies, an expansion of personalized immunotherapy solutions, increasing investment in adoptive cell transfer therapies, rising healthcare expenditure on cancer treatment, and the integration of digital platforms for patient monitoring and clinical trials. Major trends anticipated during this period include the increasing adoption of immune checkpoint inhibitors across multiple cancer types, growth in the development of cancer vaccines and adoptive cell therapies, a heightened focus on personalized immuno-oncology treatments, the expansion of hospital and ambulatory surgical center-based immunotherapy programs, and an uptick in clinical trials and research activities related to monoclonal antibodies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp

Which Primary Drivers Are Impacting The Immuno-Oncology Drugs Market Growth?

The growing occurrence of cancer cases is projected to drive the expansion of the immuno-oncology drugs market. Cancer is characterized by the uncontrolled growth of abnormal cells, potentially spreading throughout the body and impairing normal functions. The increase in cancer cases is attributed to factors such as demographic aging, evolving lifestyles, and improved detection methodologies. Immuno-oncology drugs facilitate this by stimulating the body’s immune system to target and eliminate cancer cells, thereby providing more effective and precise treatment options. For instance, in 2023, Cancer Australia, an Australia-based government agency, estimated that 164,694 new cancer cases were diagnosed and 51,269 deaths occurred, with prostate, breast, melanoma, colorectal, and lung cancers being the most prevalent, while rare cancers represented about one-third of diagnoses and 42% of deaths. Consequently, the rising incidence of cancer cases is fueling the growth of the immuno-oncology drugs market.

Which Segment Classifications Are Used In The Immuno-Oncology Drugs Market Segment Analysis?

The immuno-oncology drugs market covered in this report is segmented –

1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Other Types

2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application

3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors

3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies

4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

5) By Other Types: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies

Which Trends Are Shaping The Immuno-Oncology Drugs Market?

Key players within the immuno-oncology drugs market are forming alliances to create and market a new checkpoint antibody, aiming to improve the efficacy of cancer therapies. These strategic partnerships drive innovation by facilitating the sharing of knowledge across various disciplines, which in turn accelerates the creation of combination therapies, customized treatments, and new drug administration methods. An example of this is the collaboration in March 2023 between BioNTech SE, a company headquartered in Germany, and OncoC4 Inc, a pharmaceutical firm based in the US. They teamed up to jointly develop and commercialize a checkpoint antibody, specifically the anti-CTLA-4 monoclonal antibody candidate identified as ONC-392. The objective of this joint venture is to broaden cancer treatment alternatives for various solid tumor types.

Which Firms Are Contributing To The Immuno-Oncology Drugs Market Ecosystem?

Major companies operating in the immuno-oncology drugs market are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals.

Get The Full Immuno-Oncology Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

Which Region Holds The Highest Market Share In The Immuno-Oncology Drugs Market?

North America was the largest region in the immuno-oncology drugs market in 2025. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Immuno-Oncology Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

Browse Through More Reports Similar to the Global Immuno-Oncology Drugs Market 2026, By The Business Research Company

Veterinary Laboratory Testing Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-laboratory-testing-services-global-market-report

Dermatitis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Veterinary Diagnostic Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-diagnostic-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

April 30, 2026
Cancer Therapy Market Developments And Opportunities Across 2026–2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Cancer Therapy Market Compare Between 2026 And 2030?

The cancer therapy market size has expanded significantly in recent years. It is projected to increase from $210.44 billion in 2025 to $232.47 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.5%. Historically, this growth can be attributed to factors such as rising cancer incidence, chemotherapy adoption, hospital oncology infrastructure, radiation therapy expansion, and an aging population.

The cancer therapy market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $342.1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.1%. Factors contributing to this growth during the projected timeframe include the development of biomarker-driven therapies, an expanding immuno-oncology pipeline, increased uptake of precision medicine, escalating healthcare spending, and improved early cancer detection methods. Key developments expected in the forecast period encompass the swift embrace of immunotherapy, the proliferation of targeted cancer treatments, the broadening scope of precision oncology, a rise in the application of combination therapies, and a move towards tailored treatment regimens.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24492&type=smp

What Significant Factors Are Influencing The Cancer Therapy Market Expansion?

The future expansion of the cancer therapy market is anticipated to be driven by the rising incidence of cancer. Cancer is defined as a collection of illnesses marked by the unregulated multiplication and dissemination of atypical cells throughout the body. The primary reason for the rise in cancer cases is heightened exposure to environmental carcinogens, including pollution and tobacco smoke. Cancer therapy is vital for addressing the growing prevalence of cancer through managing existing cases, enhancing patient survival, and slowing down disease advancement. As an illustration, data from February 2024 provided by the World Health Organization (WHO), an intergovernmental organization located in Switzerland, projects that worldwide cancer incidence will surpass 35 million new cases by the year 2050. This signifies a 77% surge compared to the approximately 20 million cases documented in 2022. Consequently, the growing occurrence of cancer is a key factor propelling the cancer therapy market.

How Is The Cancer Therapy Market Categorized Across Its Segment Groups?

The cancer therapy market covered in this report is segmented –

1) By Therapy Type: Chemotherapy, Target Therapy, Immunotherapy, Radiotherapy, Other Therapy Types

2) By Cancer Type: Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynaecologic Cancer, Respiratory Or Lung Cancer, Other Cancer Types

3) By End User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers

Subsegments:

1) By Chemotherapy: Alkylating Agents, Antimetabolites, Anti-Tumor Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors, Corticosteroids, Other Chemotherapy Drugs

2) By Targeted Therapy: Monoclonal Antibodies, Tyrosine Kinase Inhibitors (TKIs), mTOR Inhibitors, Proteasome Inhibitors, PARP Inhibitors, Other Targeted Agents

3) By Immunotherapy: Immune Checkpoint Inhibitors, CAR T-cell Therapy, Cancer Vaccines, Cytokines, Oncolytic Virus Therapy, Other Immunotherapies

4) By Radiotherapy: External Beam Radiation Therapy (EBRT), Internal Radiation Therapy (Brachytherapy), Systemic Radiation Therapy, Stereotactic Radiosurgery (SRS), Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT)

5) By Other Therapy Types: Hormone Therapy, Stem Cell Transplant, Photodynamic Therapy, Cryoablation, Hyperthermia Therapy

Which Trends Are Impacting The Progress Of The Cancer Therapy Market?

Leading firms within the cancer therapy market are prioritizing the creation of advanced treatments, particularly immuno-oncology drugs, with the aim of boosting treatment efficacy by leveraging the body’s own immune defenses to identify and eliminate cancerous cells. These immuno-oncology medications represent a category of cancer therapies designed to activate or bolster the body’s intrinsic immune response for more efficient recognition and targeting of cancer cells. As an illustration, in December 2024, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical firm, launched Toripalimab in India, marking it as the initial and sole immuno-oncology drug approved for addressing nasopharyngeal cancer. This introduction provides a novel, precise therapeutic alternative for individuals afflicted by this uncommon and severe cancer, holding the potential to better patient results via sophisticated immune system interaction. The availability of toripalimab in India highlights Dr. Reddy’s dedication to broadening access to state-of-the-art cancer treatments in regions with limited options.

Which Firms Are Influencing Competition In The Cancer Therapy Market?

Major companies operating in the cancer therapy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Elekta AB, Exelixis Inc., Accuray Incorporated, Akeso Inc., Nanobiotix S.A., SOTIO Biotech a.s., AdvanCell Isotopes Pty Ltd, Axcynsis Therapeutics Pte Ltd, Clarity Pharmaceuticals Ltd, Affimed N.V., Aptadel Therapeutics S.L.

Get The Full Cancer Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-therapy-global-market-report

Which Region Leads The Cancer Therapy Market In Overall Market Size?

North America was the largest region in the cancer therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cancer Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cancer-therapy-global-market-report

Browse Through More Reports Similar to the Global Cancer Therapy Market 2026, By The Business Research Company

Oncology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-global-market-report

Blood Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Cancer Immunotherapy Drug Discovery Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-drug-discovery-outsourcing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

April 29, 2026
Cancer Therapy Market Outlook 2026–2030 Exploring Growth Opportunities

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Cancer Therapy Market Over The 2026–2030 Period?

The cancer therapy market size has experienced rapid expansion in recent years. It is projected to increase from $210.44 billion in 2025 to $232.47 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.5%. This historical growth can be attributed to factors such as rising cancer incidence, increased chemotherapy adoption, improvements in hospital oncology infrastructure, the expansion of radiation therapy, and an aging population.

The cancer therapy market size is expected to experience substantial growth in the upcoming years, expanding to $342.1 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. This growth during the forecast period can be attributed to factors such as biomarker-driven therapies, the expansion of the immuno-oncology pipeline, the adoption of precision medicine, rising healthcare expenditure, and improved early cancer detection. Prominent trends within this period include the rapid embrace of immunotherapy, the proliferation of targeted cancer treatments, the broadening scope of precision oncology, an increased reliance on combination therapies, and a shift towards personalized treatment protocols.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24492&type=smp

What Underlying Factors Are Accelerating The Growth Of The Cancer Therapy Market?

The escalating incidence of cancer is anticipated to fuel the expansion of the cancer therapy market moving forward. Cancer describes a collection of illnesses defined by the unchecked proliferation and dispersal of irregular cells within the body. The primary reason for the rise in cancer is increased exposure to environmental carcinogens such as pollution and tobacco smoke. Cancer therapy holds a critical position in addressing the increasing occurrence of cancer by treating existing cases, boosting survival rates, and slowing down disease advancement. For example, in February 2024, data from the World Health Organization (WHO), a Switzerland-based intergovernmental organization, projected that global cancer incidence will surpass 35 million new cases by 2050, indicating a 77% rise from the estimated 20 million cases recorded in 2022. Hence, the increasing prevalence of cancer is propelling the cancer therapy market.

How Is The Cancer Therapy Market Segmented Across Key Categories?

The cancer therapy market covered in this report is segmented –

1) By Therapy Type: Chemotherapy, Target Therapy, Immunotherapy, Radiotherapy, Other Therapy Types

2) By Cancer Type: Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynaecologic Cancer, Respiratory Or Lung Cancer, Other Cancer Types

3) By End User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers

Subsegments:

1) By Chemotherapy: Alkylating Agents, Antimetabolites, Anti-Tumor Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors, Corticosteroids, Other Chemotherapy Drugs

2) By Targeted Therapy: Monoclonal Antibodies, Tyrosine Kinase Inhibitors (TKIs), mTOR Inhibitors, Proteasome Inhibitors, PARP Inhibitors, Other Targeted Agents

3) By Immunotherapy: Immune Checkpoint Inhibitors, CAR T-cell Therapy, Cancer Vaccines, Cytokines, Oncolytic Virus Therapy, Other Immunotherapies

4) By Radiotherapy: External Beam Radiation Therapy (EBRT), Internal Radiation Therapy (Brachytherapy), Systemic Radiation Therapy, Stereotactic Radiosurgery (SRS), Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT)

5) By Other Therapy Types: Hormone Therapy, Stem Cell Transplant, Photodynamic Therapy, Cryoablation, Hyperthermia Therapy

Which Upcoming Trends Are Expected To Influence The Cancer Therapy Market?

Major companies within the cancer therapy market are concentrating on creating novel treatments, such as immuno-oncology drugs, to boost treatment efficacy by harnessing the body’s immune system to identify and destroy cancer cells. Immuno-oncology drugs are a class of cancer therapies designed to stimulate or enhance the body’s own immune system to recognize and attack cancer cells more proficiently. For instance, in December 2024, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical company, introduced Toripalimab in India, which is the first and only immuno-oncology medication authorized for the treatment of nasopharyngeal cancer. This launch provides a new, targeted treatment option for patients suffering from this rare and aggressive cancer, potentially improving outcomes through advanced immune system engagement. The availability of toripalimab in India underscores Dr. Reddy’s commitment to expanding access to cutting-edge cancer therapies in underserved areas.

Who Are The Dominant Players Shaping The Cancer Therapy Market Landscape?

Major companies operating in the cancer therapy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Elekta AB, Exelixis Inc., Accuray Incorporated, Akeso Inc., Nanobiotix S.A., SOTIO Biotech a.s., AdvanCell Isotopes Pty Ltd, Axcynsis Therapeutics Pte Ltd, Clarity Pharmaceuticals Ltd, Affimed N.V., Aptadel Therapeutics S.L.

Read the full cancer therapy market report here:

https://www.thebusinessresearchcompany.com/report/cancer-therapy-global-market-report

Which Region Is Projected To Dominate The Cancer Therapy Market During The Forecast Period?

North America was the largest region in the cancer therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24492&type=smp

Browse Through More Reports Similar to the Global Cancer Therapy Market 2026, By The Business Research Company

Oncology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-global-market-report

Blood Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Cancer Immunotherapy Drug Discovery Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-drug-discovery-outsourcing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

March 29, 2026
Cancer Therapy Market Outlook 2026–2030 Exploring Growth Opportunities

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Cancer Therapy Market Over The 2026–2030 Period?

The cancer therapy market size has experienced rapid expansion in recent years. It is projected to increase from $210.44 billion in 2025 to $232.47 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.5%. This historical growth can be attributed to factors such as rising cancer incidence, increased chemotherapy adoption, improvements in hospital oncology infrastructure, the expansion of radiation therapy, and an aging population.

The cancer therapy market size is expected to experience substantial growth in the upcoming years, expanding to $342.1 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. This growth during the forecast period can be attributed to factors such as biomarker-driven therapies, the expansion of the immuno-oncology pipeline, the adoption of precision medicine, rising healthcare expenditure, and improved early cancer detection. Prominent trends within this period include the rapid embrace of immunotherapy, the proliferation of targeted cancer treatments, the broadening scope of precision oncology, an increased reliance on combination therapies, and a shift towards personalized treatment protocols.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24492&type=smp

What Underlying Factors Are Accelerating The Growth Of The Cancer Therapy Market?

The escalating incidence of cancer is anticipated to fuel the expansion of the cancer therapy market moving forward. Cancer describes a collection of illnesses defined by the unchecked proliferation and dispersal of irregular cells within the body. The primary reason for the rise in cancer is increased exposure to environmental carcinogens such as pollution and tobacco smoke. Cancer therapy holds a critical position in addressing the increasing occurrence of cancer by treating existing cases, boosting survival rates, and slowing down disease advancement. For example, in February 2024, data from the World Health Organization (WHO), a Switzerland-based intergovernmental organization, projected that global cancer incidence will surpass 35 million new cases by 2050, indicating a 77% rise from the estimated 20 million cases recorded in 2022. Hence, the increasing prevalence of cancer is propelling the cancer therapy market.

How Is The Cancer Therapy Market Segmented Across Key Categories?

The cancer therapy market covered in this report is segmented –

1) By Therapy Type: Chemotherapy, Target Therapy, Immunotherapy, Radiotherapy, Other Therapy Types

2) By Cancer Type: Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynaecologic Cancer, Respiratory Or Lung Cancer, Other Cancer Types

3) By End User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers

Subsegments:

1) By Chemotherapy: Alkylating Agents, Antimetabolites, Anti-Tumor Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors, Corticosteroids, Other Chemotherapy Drugs

2) By Targeted Therapy: Monoclonal Antibodies, Tyrosine Kinase Inhibitors (TKIs), mTOR Inhibitors, Proteasome Inhibitors, PARP Inhibitors, Other Targeted Agents

3) By Immunotherapy: Immune Checkpoint Inhibitors, CAR T-cell Therapy, Cancer Vaccines, Cytokines, Oncolytic Virus Therapy, Other Immunotherapies

4) By Radiotherapy: External Beam Radiation Therapy (EBRT), Internal Radiation Therapy (Brachytherapy), Systemic Radiation Therapy, Stereotactic Radiosurgery (SRS), Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT)

5) By Other Therapy Types: Hormone Therapy, Stem Cell Transplant, Photodynamic Therapy, Cryoablation, Hyperthermia Therapy

Which Upcoming Trends Are Expected To Influence The Cancer Therapy Market?

Major companies within the cancer therapy market are concentrating on creating novel treatments, such as immuno-oncology drugs, to boost treatment efficacy by harnessing the body’s immune system to identify and destroy cancer cells. Immuno-oncology drugs are a class of cancer therapies designed to stimulate or enhance the body’s own immune system to recognize and attack cancer cells more proficiently. For instance, in December 2024, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical company, introduced Toripalimab in India, which is the first and only immuno-oncology medication authorized for the treatment of nasopharyngeal cancer. This launch provides a new, targeted treatment option for patients suffering from this rare and aggressive cancer, potentially improving outcomes through advanced immune system engagement. The availability of toripalimab in India underscores Dr. Reddy’s commitment to expanding access to cutting-edge cancer therapies in underserved areas.

Who Are The Dominant Players Shaping The Cancer Therapy Market Landscape?

Major companies operating in the cancer therapy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Elekta AB, Exelixis Inc., Accuray Incorporated, Akeso Inc., Nanobiotix S.A., SOTIO Biotech a.s., AdvanCell Isotopes Pty Ltd, Axcynsis Therapeutics Pte Ltd, Clarity Pharmaceuticals Ltd, Affimed N.V., Aptadel Therapeutics S.L.

Read the full cancer therapy market report here:

https://www.thebusinessresearchcompany.com/report/cancer-therapy-global-market-report

Which Region Is Projected To Dominate The Cancer Therapy Market During The Forecast Period?

North America was the largest region in the cancer therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24492&type=smp

Browse Through More Reports Similar to the Global Cancer Therapy Market 2026, By The Business Research Company

Oncology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-global-market-report

Blood Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Cancer Immunotherapy Drug Discovery Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-drug-discovery-outsourcing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

March 29, 2026